SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently a focal point for investors as a proposed fifteen-billion-dollar stock offering sparks intense debate over potential dilution versus the necessity of funding aggressive AI and manufacturing expansion. The community remains deeply divided, with some traders bracing for short-term price volatility while others view the pullback as a strategic buying opportunity for a long-term turnaround play.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending following a major strategic collaboration and equity investment from Boeing, which also includes the acquisition of several Boeing subsidiaries to advance their physical AI and aerospace capabilities. While bulls are excited by the potential for defense contracts and a possible short squeeze, community discussion remains polarized as some investors express concerns over dilution and the company's long-term commercialization timeline.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently under intense community scrutiny following positive topline Phase 3 IZAR-1 trial results, which showed the drug met primary and secondary endpoints in psoriatic arthritis patients. While some retail investors express frustration over perceived delays and stock price stagnation, many community members emphasize that the drug's long-term efficacy and safety profile make it a strong candidate for future acquisition, actively discussing the potential for a "best-in-class" profile as the trial remains blinded through 52 weeks.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors aggressively debate reports of a potential withdrawal of the company's multi-billion dollar bid to acquire eBay, with many weighing the implications of a possible partnership versus potential shareholder dilution. The community remains deeply divided, with some betting on a strategic '4D chess' move by leadership to unlock value while others express frustration over stagnant price action and the lack of official communication.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is trending as investors react to the appointment of Dr. Lynn Seely to the board and positive clinical developments surrounding its ABCL635 program. Community sentiment remains split between long-term bulls highlighting institutional accumulation and platform validation via new partnerships, and skeptics emphasizing past performance and concerns regarding pipeline execution.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

Tenax Therapeutics is currently experiencing intense market volatility and significant downward pressure following a Phase 3 clinical trial failure for its heart drug. While some members of the community are discouraged by the sharp decline and the risks inherent in binary biotech events, others are actively debating whether the stock is oversold, citing cash-per-share values and potential paths forward for the company.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUM is trending due to heightened investor anticipation surrounding its upcoming Q2 earnings release and a potential short squeeze, fueled by high short interest and aggressive retail discussion regarding its pivot into AI infrastructure. The community is actively debating the impact of the Northern Data acquisition and the company's long-term cloud revenue potential against its recent price volatility.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trading in a state of high volatility as investors await an update on an FDA decision that has surpassed its expected deadline. The community remains deeply divided, with bulls anticipating a breakthrough and buyout potential, while bears are aggressively shorting the stock, citing ongoing concerns over potential dilution, funding risks, and the commercial viability of its therapy.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in Japan, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

The community is actively discussing rumors of a potential hostile takeover of eBay by GameStop, with retail investors polarized over whether GameStop's CEO, Ryan Cohen, can successfully execute such a massive acquisition. While some traders are speculating on increased equity exposure and potential synergy plays, others remain highly skeptical, voicing concerns over management's strategy, potential dilution, and the overall feasibility of the deal given the board's resistance.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is generating intense market conversation driven by its first public earnings report and a high-profile lockup expiration that has triggered a battle between institutional index-tracking buyers and short sellers. Community sentiment is deeply divided, with bulls pointing to aggressive long-term revenue targets and AI infrastructure expansion while bears remain focused on valuation concerns, potential share dilution, and the sustainability of capital-intensive projects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

Key PointsDeep Track Capital bought 6,772,595 shares of Alumis last quarter; the estimated transaction value was $169.31 million (based on average prices...

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Key PointsCormorant bought 313,645 additional Alumis shares in the first quarter; the estimated trade size was $7.84 million (using average prices in the quarter...

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Key PointsOmega Fund Management sold 411,968 shares of Alumis; the estimated trade value is $10.3 million (based on quarterly average price...

This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.read more...

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +4.76% and -5.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Why One Fund's $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug

Key PointsACT Capital Management acquired 174,250 ALMS shares in the first quarter, with an estimated trade value of $4.36 million based on average first-quarter pricing...

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of -26.09% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Alumis Inc. (NASDAQ:ALMS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twelve analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy...

Alumis Inc. (NASDAQ:ALMS) Short Interest Up 25.3% in March

Alumis Inc. (NASDAQ:ALMS - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 11,230,693 shares, an increase of 25.3% from the March 15th total of 8,963,277 shares. Based on an average daily trading...

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALMSAlumis Inc.

Fundamentals

Connect Stocktwits to ChatGPT

Latest ALMS News